Diabetic nephropathy and cardiovascular diseases

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetic nephropathy is diagnosed by persistent albuminuria (microalbuminuria >30 mg/24h, macroalbuminuria >300 mg/24h) alongside diabetic retinopathy and absence of other renal diseases.
• Diabetic patients with microalbuminuria and macroalbuminuria face increased cardiovascular events and mortality, primarily due to cardiovascular disease (CVD) rather than end-stage renal failure (ESRF).

Purpose of the Study:

• To explore the link between diabetic nephropathy markers and cardiovascular complications.
• To identify underlying mechanisms contributing to cardiovascular disease in diabetic patients with albuminuria.

Main Methods:

• Diagnosis of diabetic nephropathy based on urinary albumin excretion rate (UAER).
• Assessment of cardiovascular risk factors including blood pressure, dyslipidemia, and procoagulatory state.
• Evaluation of endothelial dysfunction and markers of inflammation (C-reactive protein) and angiogenesis (VEGF).

Main Results:

• Microalbuminuria and macroalbuminuria are associated with a higher incidence of cardiovascular events and mortality.
• Traditional atherosclerosis risk factors (hypertension, dyslipidemia) are prevalent in diabetic patients with albuminuria.
• Microalbuminuria serves as a marker for generalized endothelial damage and an early event in atherogenesis, linked to inflammation and VEGF.

Conclusions:

• Diabetic nephropathy, particularly macroalbuminuria, is a strong predictor of cardiovascular morbidity and mortality.
• Multiple interconnected mechanisms, including endothelial dysfunction, inflammation, and dyslipidemia, drive cardiovascular complications in diabetic nephropathy.
• Therapeutic strategies should target these diverse mechanisms to mitigate cardiovascular risk in diabetic patients with kidney disease.